M&A Deal Summary |
|
|---|---|
| Date | 2020-06-04 |
| Target | Symphogen AS |
| Sector | Life Science |
| Buyer(s) | Servier |
| Sellers(s) |
EW Healthcare Partners
Gilde Healthcare |
| Deal Type | Add-on Acquisition |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1954 |
| Sector | Life Science |
| Employees | 22,000 |
| Revenue | 4.2B EUR (2018) |
Servier is a pharmaceutical company governed by a non-profit foundation. Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neurodegenerative diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development. Servier was founded in 1954 and is based in Suresnes, France.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 3 |
| Sector: Life Science M&A | 2 of 3 |
| Type: Add-on Acquisition M&A Deals | 1 of 1 |
| Country: Denmark M&A | 1 of 1 |
| Year: 2020 M&A | 1 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-10-01 |
CTI BioPharma - PIXUVRI
Seattle, Washington, United States CTI BioPharma Corp. - PIXUVRI is a cytotoxic medicine that works by interfering with the DNA within cells and preventing them from making more copies of DNA. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-12-21 |
Agios - Oncology Business
Cambridge, Massachusetts, United States Agios' Oncology Business is a developer of TIBSOVO® which is approved in the U.S. as monotherapy for the treatment of adults with IDH1-mutant relapsed or refractory acute myeloid leukemia (AML) and for adults with newly diagnosed IDH1-mutant AML who are ≥75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy. Agios’ oncology pipeline and clinical programs, including vorasidenib, an investigational, brain-penetrant, dual inhibitor of mutant IDH1 and IDH2 which is currently being studied in the registration-enabling Phase 3 INDIGO study in patients with IDH-mutant low-grade glioma Agios' Oncology Business is based in Cambridge, Massachusetts. |
Buy | $2.0B |
| Category | Growth Capital Firm |
|---|---|
| Founded | 1985 |
| PE ASSETS | 3.0B USD |
| Size | Large |
| Type | Sector Focused |
Essex Woodlands Health Ventures is a growth equity and venture capital specialist investment firm focused on opportunities across the healthcare sector. Specific areas of interest include biotechnology, pharmaceuticals, medical devices, and healthcare services/IT. Historically, Essex invested primarily in early and later-stage situations; however, today the firm also makes growth capital investments between $20 - $60 million in companies valued between $50 - $250 million, as well as private investments in public entities (PIPEs). Essex Woodlands was formed in 1985 and offices in Palo Alto, California; New York City; Houston, Texas; Shanghai and London.
| DEAL STATS | # |
|---|---|
| Overall | 48 of 53 |
| Sector: Life Science M&A | 16 of 17 |
| Type: Add-on Acquisition M&A Deals | 31 of 34 |
| Country: Denmark M&A | 1 of 1 |
| Year: 2020 M&A | 1 of 3 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-11-08 |
Venus Concept
Toronto, Ontario, Canada Venus Concept is a medical technology company that develops, commercializes, and delivers safe, efficacious, and easy-to-use aesthetic technologies and related practice enhancement services in a unique, industry-disruptive subscription-based business model. Venus Concept was founded in 2002 and is based in Toronto, Ontario. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-06-16 |
Proteus Digital Health
Redwood City, California, United States Proteus Digital Health is a developer of digital products that collect and aggregate various behavioral, physiological and therapeutic metrics. Proteus Digital Health is based in Redwood City, California. |
Sell | - |
| Category | Private Equity Firm |
|---|---|
| Founded | 1982 |
| PE ASSETS | 2.6B EUR |
| Size | Large |
| Type | Sector Focused |
Gilde Healthcare is a specialist private equity and venture investor focused on the healthcare sector. The Firm's buyout group targets majority investments throughout Europe (preference for Germany, the Netherlands, Belgium, Austria or Switzerland) and has a focus on healthcare providers, suppliers and service providers active in the healthcare market. The Firm's venture group looks to invest in early stage medtech, diagnostics, digital health and therapeutics companies throughout North America and Europe. Gilde Healthcare was established in 1982 and is headquartered in Utrecht, Netherlands.
| DEAL STATS | # |
|---|---|
| Overall | 27 of 35 |
| Sector: Life Science M&A | 14 of 16 |
| Type: Add-on Acquisition M&A Deals | 13 of 17 |
| Country: Denmark M&A | 3 of 3 |
| Year: 2020 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-12-18 |
BlijWerkt
Woerden, Netherlands BlijWerkt is a fast-growing occupation health provider. Supporting both large organizations and SMEs in managing absenteeism by improving the vitality of organizations and their employees. BlijWerkt manages the process of employee sick leave and returns to work. BlijWerkt was founded in 2004 and is based in Woerden, Netherlands. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-12-01 |
Noema
Basel, Switzerland Noema is developing therapies to restore functioning in patients with orphan conditions of the brain and nervous system. Noema was founded in 2019 and is based in Basel, Switzerland. |
Buy | - |
